TD Cowen Remains a Buy on Shattuck Labs (STTK)

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Shattuck Labs (STTK – Research Report). The company’s shares closed yesterday at $8.48.

According to TipRanks, Frahm is a 5-star analyst with an average return of 27.0% and a 50.29% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Theravance Biopharma, and Black Diamond Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Shattuck Labs with a $15.00 average price target, implying a 76.89% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $28.00 price target.

The company has a one-year high of $11.76 and a one-year low of $1.33. Currently, Shattuck Labs has an average volume of 350.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Shattuck Labs (STTK) Company Description:

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company’s product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.